Together, we identified a rare triple ALK fusion variant, ALK-LRRN2, LTBP1-ALK and HIP1-ALK, in a patient with lung adenocarcinoma. The patient benefited from alectinib treatment, which could provide a certain reference for the patients with such gene alteration. READ ARTICLE
Medicine DOI:10.1097/MD.0000000000027999
Authors: Ning S, Shi C, Zhang H and Li J.
